Back to News
Market Impact: 0.28
Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial
Source: Nasdaq
Healthcare & Biotech
Clearmind Medicine announced that Yale University's Institutional Review Board approved patient recruitment for Parts B and C of its Phase I/II trial of CMND-100 for alcohol use disorder. The authorization advances the clinical-development program into additional patient-recruitment stages, but no efficacy, safety, or financial results were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.38
Ticker Sentiment
CMND0.72
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Oncologists Cheer Melanoma Data
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Palantir (PLTR) Q4 2025 Earnings: 70% Revenue Growth, Then an 11% Single-Day Crash
- AlphaSense Pricing: What Public Contract Data Shows in 2026